Upgrade to SI Premium - Free Trial

Pacira Pharmaceuticals (PCRX) PT Raised to $67 at BMO Capital

February 28, 2022 8:49 AM
BMO Capital analyst Gary Nachman raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $67.00 (from $62.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View Analyst PT Change

Next Articles